iSpecimen Inc. (ISPC): Nasdaq/NYSE listing notice — iSpecimen receives Nasdaq deficiency notice for bid price below $1.00; cure deadline May 18, 2026

iSpecimen Inc.

Notice received Nov 19, 2025; stock continues trading under ISPC with no immediate delisting.
Company has 180 calendar days, until May 18, 2026, to regain compliance.
To cure, closing bid price must be at least $1.00 for ten consecutive business days.
If not cured by May 18, 2026, an additional 180-day period may be available if other listing criteria are met.
Options include a reverse stock split; failure to cure could lead to delisting and appeal rights.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

iSpecimen Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

November 19, 2025, iSpecimen Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price of the Company’s common stock had been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for the prior 30 consecutive business days. As a result, the Company is no longer in compliance with the Minimum Bid Price Requirement. The Notice has no

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

iSpecimen Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-113708

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.